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Rationale & Objective: Patients with chronic kidney disease (CKD) are particularly 
sensitive to dietary sodium.  We evaluated a self-management approach for dietary sodium 
restriction in patients with CKD. 
Study Design: Randomized controlled trial.  
Setting & Participants: Nephrology outpatient clinics in four Dutch hospitals. 99 adults 
with CKD or a functioning kidney transplant, eGFR ≥25 mL/min/1.73m
2
, hypertension, and 
sodium intake >130 mmol/day.  
Intervention: Routine care was compared with routine care plus a web-based self-
management intervention including individual e-coaching and group meetings implemented 
over a 3-month intervention period, followed by e-coaching over a 6-month maintenance 
period.  
Outcomes: Primary outcomes were sodium excretion after the 3-month intervention and after 
the 6-month maintenance period. Secondary outcomes were blood pressure, proteinuria, 
costs, quality of life, self-management skills, and barriers and facilitators for implementation. 
Results: Baseline eGFR was 55.0±22.0 mL/min/1.73m
2
. During the intervention period, 
sodium excretion fell in the intervention group from 188(SE, 8) to 148(8) mmol/day 
(P<0.001), but it did not change significantly in the control group. At 3 months, the mean 
sodium excretion was 24.8 mmol/day (95%CI, 0.1 to 49.6; P=0.049) lower in the intervention 
group. At 3 months, systolic blood pressure (SBP) fell in the intervention group from 140(3) 
mmHg to 132(3) mmHg (P<0.001), but was unchanged in the control group. The mean 
difference in SBP across groups was ‒4.7 (‒10.7 to 1.3, P=0.1) mmHg. During the 
maintenance phase, sodium excretion rose in the intervention group, but remained lower than 
at baseline at 160(8) mmol/day (P=0.01), while it fell in the control group from 174(9) at the 
end of the intervention period to 154(9) mmol/day (P=0.001). Consequently, no difference in 
4 
 
sodium excretion between groups was observed after the maintenance phase. There was no 
difference in SBP between groups after the maintenance phase.  
Limitations: Limited power, post-randomization loss to follow-up, Hawthorne effect, lack of 
dietary data, short-term follow-up. 
Conclusions: A coaching intervention reduced sodium intake at 3 months. Efficacy during 
the maintenance phase was diminished, possibly due to inadvertent adoption of the 
intervention by the control group.  
Funding body The Netherlands Organization for Health Research and Development 
(ZonMw) project 837001005, Doelmatigheidsonderzoek 2013-2015. Dutch Kidney 
Foundation, project code PV48. 
Trial registration ClinicalTrials.gov identifier NCT02132013 
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Plain-language summary of article 
The SUBLIME lifestyle intervention aimed to reduce sodium intake and blood pressure in 
hypertensive patients with chronic kidney disease (CKD). Hypertension is common in 
patients with CKD and is usually treated with multiple medications. High sodium intake is a 
major contributor to hypertension, but is not effectively targeted in routine care. This is 
partially because improving dietary habits and reduction of sodium intake is not easy for most 
people, and requires substantial coaching and costs to achieve. SUBLIME helped patients to 
reduce their sodium intake. However, over time the effects somewhat diminished, and further 




Patients with chronic kidney disease (CKD) are particularly sensitive to excess sodium
1
, and 
are strongly advised to limit sodium intake.
2–4
 Observational studies revealed the potential of 
moderately reduced sodium intake, suggesting every gram less sodium intake is associated 
with a 15% lower risk of cardiovascular complications, a 15% lower risk for end stage renal 
disease (ESRD) in diabetic CKD
5




Current approaches to reduce sodium intake are largely unsuccessful: an analysis of >10,000 
CKD patients revealed that average sodium intake in CKD patients was 164 mmol/day, even 
in the dedicated setting of the nephrology outpatient clinic.
7
 Behavioral approaches may be 
more fruitful in achieving sodium restriction.
8,9
 Hypertensive patients receiving behavioral 
counseling in the Trials of Hypertension Prevention I and II had a 25% lower risk of 
cardiovascular events after 10‒15 years follow-up.
8
 Likewise, the Effects of Self-monitoring 
on Outcome of Chronic Kidney Disease (ESMO) study, which was based on self-regulation 





Several studies showed that self-regulation theory-based interventions are associated with 
good outcomes.
10–14
 A qualitative study in CKD on barriers and facilitators for sodium 
restriction yielded several recommendations for future intervention.
14
 More recently, a 
quantitative study in CKD revealed barriers to target for achieving sodium reduction.
15
 
Recommendations from these studies were incorporated in the present self-regulation theory-
based study.  
One-to-one counseling required in behavioral interventions is costly. Use of E-Health may 
improve affordability. To investigate this, we designed the SodiUm Burden lowered by 
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Lifestyle Intervention: self-Management and E-health technology (SUBLIME). The 
SUBLIME intervention included group counseling and a web-based self-management 
program, and was followed by a maintenance phase. We evaluated the SUBLIME 
intervention for efficacy and explored costs, barriers and facilitators for implementation of 




SUBLIME was a randomized controlled trial that compared routine care with routine care 
plus a web-based self-management dietary sodium reduction intervention delivered through 
individual e-coaching and group meetings during a 3-month intervention period, followed by 
e-coaching during a 6-month maintenance period.   
Participants 
Participants were recruited from June 2014 to March 2015 at nephrology outpatient clinics of 
the four participating centers in the Netherlands: Leiden University Medical Center, Leiden; 
St. Antonius Hospital, Nieuwegein; University Medical Center Groningen, Groningen; and 
ZGT Hospital, Almelo. Inclusion criteria were age ≥18 years; CKD stages 1–4, and renal 
transplant recipients (RTR) if estimated glomerular filtration rate (eGFR) was ≥25 
mL/min/1.73m
2
(no upper limit); urinary sodium excretion at the last two visits >130 
mmol/day or >150 mmol/day at the last visit; systolic blood pressure (SBP) >135 mmHg or 
diastolic blood pressure (DBP) >85 mmHg or well-controlled BP with antihypertensive 
therapy; sufficient command of the Dutch language; ability to use the Internet; and written 
informed consent. Exclusion criteria were rapidly and persistently progressive renal function 
loss, not from acute, intermittent origin; SBP >170 mmHg, or DBP >95 mmHg, or SBP <95 
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mmHg not responding to withdrawal of antihypertensive medications; history of 
cardiovascular events <6 months ago; renal transplantation <1 year ago; medical conditions 
likely to interfere with the completion of the study; previous participation in a similar study.  
 
The medical ethics board approved the study protocol (METc2014/075). The study is 




Participants visited outpatient clinics at baseline, 3, and 9 months for anthropomorphic and 
BP measurements; blood sampling; 24-hour urine collection; assessment of medication use; 
and filled out a questionnaire at each time point. The baseline questionnaire was distributed 
directly after randomization, as the baseline questionnaire was different for intervention and 
control group.  
 
Figure 1 presents a schematic overview of the SUBLIME intervention delivered to the 
participants randomized to the intervention group during the 3-month intervention phase and 
during the maintenance phase. The coaching was done by dietitians, lifestyle coaches or 
research nurses, who were trained by certified lifestyle professionals (i.e. professionals with a 
degree in Lifestyle Counseling). The 3-month intervention began with baseline face-to-face 
intake, when a home BP monitoring device (Microlife Watch BP Home) was distributed. The 
coach also gave participants access and instructions to a web-based self-management 
program dedicated to sodium restriction. This program consisted of modules addressing self-
regulation theory components; exercises to strengthen intrinsic motivation; self-monitoring 
with a detailed interactive food diary (designed to visually show the effect of  different food 
choices on sodium intake), self-efficacy (identifying barriers and possible solutions), goal 
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setting, social support, dealing with relapse; and a summary page delineating a ‘Plan for 
Change’. Coaches then viewed the Plan for Change and applied motivational interviewing 
supporting patients in attaining goals. Participants and their partners were invited to attend 
two scheduled 2-hour group coaching sessions (Figure 1) during the 3-month intervention 
phase. Group size ranged from 3-12 participants. During these sessions the coach addressed 
self-monitoring, skills to decline salty snacks, relapse prevention, and knowledge about 
‘hidden’ sodium in processed foods. During the 3-month intervention phase, participants also 
received individual coaching via telephone or email (e-coaching), with a minimum of two 
individual coaching sessions. During the 6-month maintenance phase, participants were 
instructed to complete web-based self-management modules and participants could receive 
1–4 individual e-coaching sessions (Figure 1). 
 
Outcomes 
The primary outcome of sodium excretion was measured by one 24-hour urine collection. 
Blood and urinary electrolytes were measured with routine laboratory procedures. Secondary 
outcomes were BP, costs, proteinuria, health-related quality of life, and self-management 
skills, and evaluation of barriers and facilitators for implementation. eGFR was calculated 
with the CKD Epidemiology Collaboration formula.
16
 BP was measured at the outpatient 
clinic, in upright position, after 5 minutes rest with an automated oscilometric device 
(WatchBP Home, Microlife), three times with a 1-minute interval.
17
 The mean of the second 
and third reading was used for analysis. Proteinuria was measured in 24-hour urinary 
collection. Changes in number of prescribed medications and dosage were explicitly asked at 
the end of the intervention phase and the maintenance phase, and were registered in the Case 





, and Partners In Health scale.
20
 Health-related quality of life was measured 
9 
 
using the Short Form (SF)-12. Scoring ranged from 0-100, higher scores indicating better 
quality of life. Self-management skills were assessed using the Partners In Health (PIH) 
scale. A four-item questionnaire was used after the active intervention-maintenance phase, 
assessing patients’ healthcare consumption. Additionally, data on medication use (type and 
dosage) and time receiving E-coaching were gathered. These healthcare consumption data 
were used for explorative calculation of healthcare costs, to explore affordability of the 
intervention.
21
 Case Report Forms were used to ascertain medical- and travel expenses. Sick 
leave from work was assessed using two questions in the baseline questionnaire. Relevant 
cost categories were consultations with the nephrologist, the general practitioner, the 
dietician, nursing days, sick leave, and travel expenses.  
 
After completion of the study we organized focus groups to evaluate the intervention and 
identify barriers and facilitators for implementation. The focus groups were led by 
representatives of the Dutch Kidney Patients Association, each session was observed by two 
note-takers from a third party. One note-taker attended all four focus groups (W.O.), her 
registration served as basis for qualitative analysis and was confirmed by the second observer 
from (O.A.B.H.). 









To detect a difference of 2 grams salt (corresponding to 34 mmol sodium/day), achieve a 2-
sided significance of 0.05, a power of 80%, and accounting for 10% drop-out, 42 patients 
were required in each group. Based on data from previous studies
9,23–25
 expected standard 
deviation was 40 mmol/day.  
 
Randomization  
Randomization was performed by an independent data management organization. The  
SURVEYSELECT procedure was used for randomization using the software program SAS 
(Cary, North Carolina, USA). Participants were stratified per participating center ensuring 
equal group size. Until all participants were allocated, randomization was concealed from 
research staff. Upon receipt of signed informed consent, the local study coordinator allocated 
a study number and contacted the data management center to receive the randomization 
result.  
 
Statistical Analysis  
Data are reported as mean±standard deviation (SD) and mean (SE) for normally distributed 




 quartile) for skewed continuous data. Categorical data are 
reported as frequency. We performed an intention-to-treat analysis on primary and secondary 
outcomes using linear mixed-effects model analysis (LMM) with restricted maximum 
likelihood approach and scaled identity covariance structure for sodium excretion, SBP and 
DBP at baseline, 3-, and 9 months, using all three time points in one model. Fixed effects 
were treatment group, time, and time × treatment group, random effect was participant 
number. We report estimated marginal means and standard error (SE) for continuous 
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outcomes in our LMM. Within-group differences over time of sodium excretion and BP were 
tested using paired samples t-test. 
 
Within-group differences over time of PIH and SF-12  were tested using Wilcoxon Signed 
Rank test. Between-groups differences of PIH and SF-12 were tested using Mann-Whitney 
test.  Mean change from to baseline of intervention compared to control of PIH and SF-12 
was tested using independent samples t-test. Occurrence of antihypertensive dose reduction 
or increase between control and intervention was compared with Fisher’s exact test.  
 
P-values <0.05 were considered statistically significant. Analyses were performed with 




We randomized 99 patients: 52 intervention and 47 control (Figure 2). Five patients did not 
attend baseline measurements. Participants were 56.6±12.4 years old, and 44% were RTR. 
Baseline characteristics were similar between control and intervention groups (Table 1). Five 
participants were lost to follow-up (Figure 2), and not all participants returned their 24-hour 
urine collection after baseline.  
 
Logging-data revealed that 44/50 participants used the program, with most participants using 
the program the first 2‒4 months. A total of 1647 recordings of dietary intake were registered 
(37.4 days per participant) during the study. Participants registered 4256 (55.4%) meals and 
3428 (44.6%) snacks. Eight participants stopped registering within one month, 11 registered 
12 
 
for >6 months. Within the period that the participants registered, most registered every other 
day. 
 
Outcomes after 3-Month Intervention Phase 
In the intervention group, sodium excretion reduced from 188±63 mmol/day to 148±55 
mmol/day at three months (Figure 3). LMM confirmed that this was a significant reduction 
with estimated marginal mean (EMM) from 188(SE, 8) to 148(8) mmol/day (P<0.001 for 
within-group difference) at three months (Table 2). The control group demonstrated a 
nominally but non-significant reduction in sodium excretion. Compared with control, this 
reflected an effect of the intervention of ‒24.8 (95%CI, ‒49.6 to ‒0.1; P=0.049 for between-
group difference) mmol/day (Table 2). There was a concomitant drop in SBP from 140±16 to 
131±14 mmHg; and DBP from 84±9 to 80±9 mmHg in the intervention group (Figure 4). 
LMM confirmed this with EMM from 140(3) to 132(3) mmHg (P<0.001 for within-group 
difference, Table 2). In comparison, SBP in control changed non-significantly from 139(3) to 
136(3) (P=0.2 for within-group difference). The mean difference in SBP across groups was ‒
4.7 (‒10.7 to 1.3, P=0.1) mmHg. After the intervention phase, eleven participants had 
proteinuria ≥1.0 g/d (6 intervention, 5 control). Median proteinuria compared to baseline did 
not markedly change in the intervention group (P=0.07 for within-group difference), nor in 
the control group (P=0.2 for within-group difference). 
 
Antihypertensive drug use in the control group reduced in 1 and increased in 3 participants 
whereas it reduced in 5 and increased in 3 participants in the intervention group (Fisher’s 
exact test, P=0.2 for dose-reduction, P=0.9 for dose-increase). Participants received 2.8±1.2 
times E-coaching. Four participants had 1 E-coaching moment and 8 did not request/ receive 




Outcomes after 6-Month Maintenance Phase 
The effect on sodium excretion persisted in the intervention group at 157±64 mmol/day 
(Figure 3). LMM confirmed this with EMM from 188(8) to 160(8) mmol/day (P=0.01 for 
within-group difference, Table 2). Control demonstrated a reduction to 154±40 mmol/day 
(Figure 3). This is reflected in LMM (Table 2), demonstrating no significant between-group 
difference in sodium excretion between intervention and control group (Table 2). A drop in 
SBP was observed from 140±16 to 131±14 mmHg in the intervention group (Figure 4). 
LMM confirmed this with EMM from 140(3) to 132(3) mmHg (P<0.001 for within-group 
difference, Table 2). In comparison, SBP in control decreased from 139(3) to 135(3) (P=0.1 
for within-group difference). The mean difference in SBP across groups was -4.3 (-10.2 to 
1.7, P=0.2). After the maintenance phase, eleven participants had proteinuria ≥1.0 g/d (5 
intervention, 6 controls). Median proteinuria compared to baseline did not markedly change 
after the maintenance phase in the intervention group (P=0.07 for within-group difference), 
nor in control (P=0.3 for within-group difference).  
 
Antihypertensive drug use reduced in 5 participants and increased in 3 participants, in both 
control and intervention (Fisher’s exact test, both P=0.9). Participants received 2.1±0.6 times 
E-coaching, 17 participants did not request or receive E-coaching (5 due to drop-out) 
according to the coaches’ logs. 
 
Quality of Life and Self-Management Skills 
At baseline, PHS was similar between groups (P=0.87, Table 3). After the intervention phase, 
PHS was higher in intervention compared with control (P=0.04), this difference remained 
after the maintenance phase (P=0.01). At baseline, MHS was similar between groups 
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(P=0.75), and remained so after the intervention phase (P=0.11). After the maintenance 
phase, the intervention group reported higher MHS than controls (P=0.01). 
At baseline, PIH-score was similar between groups (P=0.11, Table 3). Likewise, after the 
intervention and maintenance phase, no between-group differences in PIH-score were 
observed (P=0.63 and P=0.53, respectively). 
 
Costs 
The average total costs per patient for the 9-month intervention were $506 (€451) in the 
intervention group and $460 (€410) in the control group. This difference in costs are mainly 
explained by higher costs in dietary care intervention versus control. 
 
Barriers and Facilitators for Implementation: Focus Groups  
Twenty-one intervention participants participated in focus groups. Additionally, 5 partners 
and 1 daughter took part. Each focus group consisted of 5‒6 participants per center. Although 
all intervention components were evaluated, the focus groups focused on the web-based self-
management program. The participants deemed the exercises in the program clearly 
formulated and user-friendly, but questioned whether it was necessary to complete exercises 
that addressed motivation “because we were already motivated, otherwise we would not have 
participated”. The most reported barrier for using the program was filling out the interactive 
diary as this was time-intensive; not all products were available in the database, or hard to 
find. Another barrier was difficulty estimating sodium content from restaurant meals or 
combined products. Participants generally valued the ‘options for change’ menu, where 
alternative food products could be chosen. Participants expressed they used the ‘change 




When asked to what extent the modules gave insight in actual sodium consumption, 
participants reported they highly valued the monitoring module (average 8.3/10). This 
module gave visual feedback, showing the amount of sodium participants consumed by 
consuming certain foods, and how this added up compared with their self-determined goal of 
maximal daily sodium consumption.  
 
Most participants valued the e-coaching, and mentioned the importance of personal contact 
with the coach prior to the e-coaching. The majority would have appreciated “an 
unannounced reminder contact” in the maintenance phase to aid their program adherence. 
The group meetings were valued for practical advice, rise of awareness, exchange of 
experiences and contact with fellow patients. Participants stressed the importance of 
partner/family support. Two partners of participants reported their own antihypertensive 
medication was reduced. Participants appreciated the objective feedback on 24-hour sodium 
excretion and blood pressure as helpful to reduce sodium intake and would have liked even 
more frequent feedback in the form of objectively measured parameters, such as urinary 
sodium excretion. Overall, participants valued participation in SUBLIME with 7.8/10, and 
would recommend use of the program to others. 
 
Process evaluation and fidelity 
The web-based self-management program was used by 44 unique users. Although 
participants were instructed to use the program throughout the intervention, focus groups 
revealed that it was used primarily in the first months. During the first months, the program 
was used intensively; daily or every few days. Only few participants used the program >6 
months, which is supported by the logging data. Most participants registered their dietary 
16 
 
intake in the evenings. Registrations were spread over the categories of meals; breakfast 
(19%), lunch (19%), and dinner (18%), and to a lesser extent snacks in the morning (14%), 
afternoon (14%) and evening (16%). Participants appreciated the feedback on 24-hour 
sodium excretion and blood pressure as helpful to reduce sodium intake and would have liked 
even more frequent feedback by objective data. Furthermore, participants mentioned the 
importance of personal contact with the coach prior to the e-coaching. Finally, support of 
partner and family was mentioned as an important factor in reducing sodium intake. 
 
Regarding the evaluation with the providers, 8 out of 11 filled out the MIDI questionnaire. 
The providers indicated that the web-based self-management program gave them better 
insight in the situation of the participants, particularly their motivation, activities, and 
nutrition intake. A disadvantage was the time needed to familiarize oneself with the program 
and to use it. The providers felt they were capable of doing the activities needed to carry out 






In this small and short-term trial, we demonstrated that the SUBLIME intervention 
reduced sodium intake after the 3-month intervention phase. After the maintenance phase, 
sodium intake decreased in both groups, suggesting that the apparent efficacy during the 
maintenance phase may have been diminished by inadvertent adoption of the intervention by 
the control group. BP decreased from baseline, without between-groups differences at 3 
months and at 9 months post-baseline. 
The effect we observed on sodium intake is comparable to interventions in other 
populations. The PREMIER study in untreated (pre)hypertensive patients consisted of 
biweekly behavioral counseling in the first half year aiming at weight reduction alone, or 
combined with adherence to the DASH-diet, or advice-only.
26
 Sodium excretion was reduced 
with 31.6, 32.6 and 20.6 mmol/day respectively, which is comparable to the 41 mmol/day 
change achieved in our intervention phase, and also in line with 44 and 33 mmol/day 
reductions achieved in the TOHP-trials.
8
 Few studies investigated behavioral interventions in 
CKD for sodium restriction. The MASTERPLAN study, performed in a setting similar as 
SUBLIME, was a nurse-led intervention with eleven treatment targets, including adherence 
to sodium intake <2000 mg (90 mmol) per day.
27
 MASTERPLAN did not address all 
components of self-regulation theory and had a long intervention phase of two years, 
averaging 7.2 outpatient clinic visits yearly.
27,28
 MASTERPLAN had no effect on sodium 
excretion (150 versus 148 mmol/day).
28
 A multidisciplinary behavioral approach was shown 
effective in the ESMO intervention in CKD, which also successfully reduced sodium 
excretion and BP in the short term.
9
 
Higher sodium intake correlates with higher antihypertensive drug use in 141 patients 
with CKD stage 4 and 5.
29
 In SUBLIME there was more dose-reduction in the intervention 
18 
 
group after the intervention phase, while after the maintenance phase both groups displayed a 
similar incidence of dose-reduction, in line with the effects on sodium intake. 
The study has several strengths. The intervention was based on a sound theoretical 
framework and was designed in a multidisciplinary setting, with input from psychologists, 
nephrologists, dietitians, representatives from the Dutch Kidney Patients Association, and in 
co-creation with patients. Our study population consisted of several CKD stages, and also 
included RTR as these patients also commonly have hypertension and high sodium intake.
30
 
Further, the intervention was evaluated using logging data and focus groups to identify 
barriers and facilitators for implementation in clinical practice. 
Limitations of the study include lack of dietary data, and post-randomization loss to 
follow-up, short-term follow-up, and small sample size. Statistical power was limited first, by 
sample size, and second, because the power calculation was based on the treatment effect 
observed in the ESMO-study, i.e. a reduction of 30.3 mmol/day. We anticipated a larger 
effect for the present study but this was apparently overly optimistic, particularly for the 
maintenance phase. Furthermore, the preponderance of male participants in our study may 
affect generalizability. Finally, sodium intake may have been subject to the so-called 
Hawthorne-effect.
31
 Participants’ awareness of being in a sodium intervention study might 
have affected the outcome even without exposure to the intervention. For instance, control 
participants might have become more vigilant about sodium intake simply by being enrolled 
in the SUBLIME study.  Frequent 24-hour urinary sodium measurements during the study 
may have motivated control participants to achieve gradual, significant, reduction in sodium 
intake that was observed, even without the active coaching. The different time course of 
sodium reduction between the groups may be of interest. In the intervention group, the largest 
sodium reduction occurred during the intervention phase, i.e. when participants most actively 
used the web-based self-management program, as evidenced by the logging data. In the focus 
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groups, participants reported that their acquired insights into their diet affected their use of 
the web-based self-management program.  As well, they indicated that after achievement of 
their target sodium intake they stopped using the program regularly, which occurred when 
sodium reduction became similar to that in the control group. A logical interpretation would 
be that a combination of selection effect (motivation for sodium reduction), awareness of 
being studied, and feedback from urinary sodium exerted a gradual effect on sodium intake 
that was accelerated and intensified by the coaching program. 
The feedback by our participants obtained in the focus groups provides important 
lessons from our study for future interventions. First, participants considered feedback from 
objective data, such as 24-hour urine sodium, highly useful. Second, they desired face-to-face 
contact with their personal coach prior to E-coaching sessions, thus favoring blended care 
over a pure e-Health approach. Moreover, they considered social support from partner and 
family essential. Also, the intervention should be tailored to personal sodium-reduction 
barriers, and to personal preferences, such as whether or not to participate in group sessions. 
Finally, the web-based self-management program should be user-friendly. Future studies 
should elucidate whether effectively accounting for these factors can further enhance the 
efficacy of sodium management in patients with CKD on a long-term basis, and whether 
these principles can also be applied for management of other dietary factors.  
In conclusion, the SUBLIME study presents a potentially effective strategy for dietary 
sodium restriction in CKD in clinical practice, although future larger and longer term studies 
are needed to test long-term efficacy.  
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Table 1. Baseline Characteristics. 
 Total  Control  Intervention 
n 94  44  50 
Age, years 56.6 ± 12.4  58.2 ± 13.2  55.1 ± 11.5 
Female gender, n 15 (16%)  8 (18%)  7 (14%) 
eGFR (CKD-EPI), mL/min/1.73m2 55.0 ± 22.0  54.3 ± 21.6  55.6 ± 22.6 
History of DM, none 65 (69%)  30 (68%)  35 (70%) 
  DM I 7 (7%)  3 (7%)  4 (8%) 
  DM II  22 (23%)  11 (25%)  11 (22%) 
History of Dialysis, n 27 (29%)  12 (27%)  15 (30%) 
Renal Transplant Recipient, n 41 (44%)  19 (43%)  22 (44%) 
Antihypertensive drug use, n  90 (96%)  41 (93%)  49 (98%) 
Number of classes  2.0±1.0  2.0 ± 1.1  2.1 ± 1.0 
RAAS-blockade, n 70 (74%)  32 (73%)  38 (76%) 
Beta-blocker, n 41 (44%)  15 (34%)  26 (52%) 
Calcium channel antagonist, n 33 (35%)  16 (36%)  17 (34%) 
Diuretic, n 40 (43%)  22 (50%)  18 (36%) 
Calcineurin-inhibitor use 27 (29%)  12 (27%)  15 (30%) 
Possession of HBPM 64 (68%)  35 (80%)  29 (58%) 
Uses never 11 (17%)  6 (17%)  5 (17%) 
Uses daily 5 (8%)  2 (6%)  3 (10%) 
Uses weekly 19 (30%)  10 (9%)  9 (31%) 
Uses monthly 29 (45%)  17 (49%)  12 (41%) 
Body mass index, kg/m2 28.6 ± 5.3  28.4 ± 5.0  28.7 ± 5.6 
Caucasian, n  89 (95%)  40 (91%)  49 (98%)  
Higher educated, n 39 (41%)  19 (43%)  20 (40%) 
 
Abbreviations: eGFR, estimated glomerular filtration rater; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration formula; DM, diabetes mellitus; RAAS, renin‒angiotensin‒aldosterone 
system; HBPM, home blood pressure monitor.  
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Table 2. Linear Mixed Effects Model of the SUBLIME Intervention  
 Mean
a
 (SE)  Intervention  Mean
a
 (SE)  Control  Effect of Intervention (95% CI)
b 
 0  3 9 0 3 9 ∆ 0-3 months ∆ 0-9 months 























(‒49.6 to ‒0.1) 
N=85 
 6.9 
(‒17.8 to 31.6) 
N=80 



















(‒10.7 to 1.3) 
N=84 
‒4.3  
(‒10.2 to 1.7) 
N=80 























(‒5.5 to 2.0) 
N=84 
‒1.5  
(‒5.2 to 2.3) 
N=80 
a Estimated marginal means and standard error (SE).  
b Effect of interaction term time × treatment with 95% confidence interval (CI), these N refer to the 
number of participants that had both baseline and follow-up outcome measurements available. 
† P<0.001 versus baseline within group; cP=0.01 versus baseline within group; dP=0.001 versus 
baseline within group; eP=0.03 versus baseline within group; * P=0.049 difference in change versus 
control group.   
Abbreviations: SE, standard error; CI, confidence interval; N, Numbers analyzed; BP, blood pressure;  
 
Table 3. Self-management skills and health-related quality of life 
 Median [IQR]  Intervention Median [IQR]  Control 
 0  3 9 0 3 9 










































Data are shown as median [IQR], and comparisons were made with Mann Whitney between groups 
and Wilcoxon Signed Rank within groups. MHS, Mental Health Summary score; PHS, Physical Health 
Summary score; PIH, Partners in Health scale; SF, Short Form. Cronbach’s Alpha of PIH: 0.93. 
Cronbach’s Alpha of SF-12: 0.86 for PHS and 0.84 for MHS. 




Legends to Figures 
 
Figure 1. Schematic overview of the SUBLIME intervention 
Figure 2. CONSORT Flow diagram of the SUBLIME intervention.  
Figure 3. Sodium excretion as assessed by 24-hour urine collection at baseline, after 
intervention (3 months) and maintenance phase (9 months). Within-group change at 9 months 
compared to baseline (paired samples t-test) was for intervention P=0.01 and for control 
P=0.001. * denotes P=0.049 versus control group. Error bars represent standard error of 
mean.  
Figure 4. Office BP, after intervention (3 months) and maintenance phase (9 
months).Within-group change in SBP at 9 months compared to baseline (paired samples t-
test) was for intervention P<0.001 and for control P=0.09. Within-group change in DBP at 9 
months compared to baseline (paired samples t-test) was for intervention P<0.001 and for 
control P=0.03. Error bars represent standard error of mean. SBP, Systolic Blood Pressure; 
DBP, Diastolic Blood Pressure. 
